<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001475597</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001712762</issuerCik>
        <issuerName>bioAffinity Technologies, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>09076W406</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3300 NACOGDOCHES ROAD</com:street1>
          <com:street2>SUITE 216</com:street2>
          <com:city>SAN ANTONIO</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>78217</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>HRT FINANCIAL LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>127132.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>127132.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>127132.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>10.9</classPercent>
      <typeOfReportingPerson>BD</typeOfReportingPerson>
      <comments>The percentage reported herein is based on 1,166,625 shares of Common Stock outstanding as of
September 30, 2026, as reported by bioAffinity Technologies, Inc. in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026, plus 986 shares of Common Stock issuable upon the exercise of certain warrants held by HRT Financial LP, for a denominator of 1,167,611 shares.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>bioAffinity Technologies, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TEXAS, 78217.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>HRT Financial LP, a Delaware limited partnership</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>c/o Hudson River Trading LLC, 3 World Trade Center, 175 Greenwich Street, 76th Floor, New York, NY 10007</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>BD</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>The ownership information reported herein is as of September 30, 2026.

The reported aggregate amount includes 126,146 shares of Common Stock held directly and 986 shares of Common Stock issuable upon the exercise of certain warrants held by the Reporting Person.

The response to Row 9 of the cover page is incorporated herein by reference and sets forth the information required by this item.

</amountBeneficiallyOwned>
        <classPercent>The response to Row 11 of the cover page is incorporated herein by reference and sets forth the information required by this item.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>The response to Row 5 of the cover page is incorporated herein by reference and sets forth the information required by this item.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>The response to Row 6 of the cover page is incorporated herein by reference and sets forth the information required by this item.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>The response to Row 7 of the cover page is incorporated herein by reference and sets forth the information required by this item.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>The response to Row 8 of the cover page is incorporated herein by reference and sets forth the information required by this item.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>HRT FINANCIAL LP</reportingPersonName>
      <signatureDetails>
        <signature>Adam Nunes</signature>
        <title>CEO</title>
        <date>11/19/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
